Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 2, 2016, Pages 415-422

  Numata, Koji ^a   Oshima, Takashi ^a   Sakamaki, Kentaro ^b   Yoshihara, Kazue ^a   Aoyama, Toru ^c   Hayashi, Tsutomu ^d   Yamada, Takanobu ^a   Sato, Tsutomu ^c   Cho, Haruhiko ^c   Shiozawa, Manabu ^c   Yoshikawa, Takaki ^c   Rino, Yasushi ^a   Kunisaki, Chikara ^d   Akaike, Makoto ^c   Imada, Toshio ^a   Masuda, Munetaka ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Gastric cancer; IGF1R; Prognosis; S 1

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG COMBINATION; IGF1R PROTEIN, HUMAN; MESSENGER RNA; OTERACIL; S 1 (COMBINATION); SOMATOMEDIN RECEPTOR; TEGAFUR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BIOSYNTHESIS; CANCER STAGING; DRUG COMBINATION; FEMALE; GASTRIC MUCOSA; GENE EXPRESSION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DRUG COMBINATIONS; FEMALE; GASTRIC MUCOSA; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; RECEPTORS, SOMATOMEDIN; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 84955685507     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-2039-6     Document Type: Article

References (34)

1. Adachi Y et al (2009) Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin. Carcinogenesis 30:1305–1313. doi:10.1093/carcin/bgp134
2. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541–6551
3. Belham C, Wu S, Avruch J (1999) Intracellular signalling: PDK1—a kinase at the hub of things. Curr Biol 9:R93–R96
4. Blakesley VA, Stannard BS, Kalebic T, Helman LJ, LeRoith D (1997) Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 152:339–344
5. Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 60:1101–1107
6. Dallas NA et al (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69:1951–1957. doi:10.1158/0008-5472.CAN-08-2023
7. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278:687–689
8. Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10:262–267
9. Dudek H et al (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275:661–665
10. Ferlay J et al (2014) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. doi:10.1002/ijc.29210
11. Furstenberger G, Senn HJ (2002) Insulin-like growth factors and cancer. Lancet Oncol 3:298–302
12. Galamb O, Sipos F, Molnar B, Szoke D, Spisak S, Tulassay Z (2007) Evaluation of malignant and benign gastric biopsy specimens by mRNA expression profile and multivariate statistical methods. Cytometry B Clin Cytom 72:299–309. doi:10.1002/cyto.b.20189
13. Ge J, Chen Z, Wu S, Chen J, Li X, Li J, Yin J (2009) Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 80:148–158. doi:10.1159/000226089
14. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62:2942–2950
15. Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C (2008) IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128:1499–1505. doi:10.1038/sj.jid.5701185
16. Hopkins A, Crowe PJ, Yang JL (2010) Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol 136:639–650. doi:10.1007/s00432-010-0792-0
17. Imsumran A et al (2007) Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 28:947–956. doi:10.1093/carcin/bgl247
18. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. doi:10.1038/bmt.2012.244
19. Kharbanda S et al (1997) Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 94:6939–6942
20. Li H et al (2011) Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer 117:3135–3147. doi:10.1002/cncr.25893
21. Long L, Rubin R, Baserga R, Brodt P (1995) Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 55:1006–1009
22. Long L, Rubin R, Brodt P (1998) Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 238:116–121. doi:10.1006/excr.1997.3814
23. Ludovini V et al (2009) High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20:842–849. doi:10.1093/annonc/mdn727
24. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J (2000) High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 85:3653–3660. doi:10.1210/jcem.85.10.6906
25. Mazumdar M, Smith A, Bacik J (2003) Methods for categorizing a prognostic variable in a multivariable setting. Stat Med 22:559–571. doi:10.1002/sim.1333
26. Min KW (2010) Gastrointestinal stromal tumor: an ultrastructural investigation on regional differences with considerations on their histogenesis. Ultrastruct Pathol 34:174–188. doi:10.3109/01913121003689075
27. Pavelic K, Kolak T, Kapitanovic S, Radosevic S, Spaventi S, Kruslin B, Pavelic J (2003) Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol 201:430–438. doi:10.1002/path.1465
28. Sakuramoto S et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820. doi:10.1056/NEJMoa072252
29. Sasako M et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393. doi:10.1200/JCO.2011.36.5908
30. Shiraishi T, Mori M, Yamagata M, Haraguchi M, Ueo H, Sugimachi K (1998) Expression of insulin-like growth factor 2 mRNA in human gastric cancer. Int J Oncol 13:519–523
31. Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z (1996) Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 56:1761–1765
32. Valsecchi ME et al (2012) Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer 118:3484–3493. doi:10.1002/cncr.26661
33. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB (2002) Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95:2086–2095. doi:10.1002/cncr.10945
34. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619–628